| Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy--results of the first French prospective study for the French Society of Pediatric Oncology. | |
| | |
MedLine Citation:
|
PMID: 14673044 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To evaluate a strategy aimed at avoiding radiotherapy during first-line treatment of children with progressive optic pathway tumors (OPT), by exclusively administering multiagent chemotherapy during 16 months. PATIENTS AND METHODS: Between 1990 and 1998, 85 children with progressive OPT were enrolled onto this multicenter nationwide trial. Chemotherapy alternating procarbazine plus carboplatin, etoposide plus cisplatin, and vincristine plus cyclophosphamide was given every 3 weeks. At the time of relapse or progression, second-line chemotherapy was authorized before recourse to radiotherapy. RESULTS: Objective response rate (partial response [PR] + complete response [CR]) to chemotherapy was 42%. Five-year progression-free survival (PFS) and overall survival rates were 34% and 89%, respectively. The 5-year radiotherapy-free survival rate was 61%. In the multivariate analysis of the 85 patients that entered onto the study, factors associated with the risk of disease progression were age younger than 1 year at diagnosis (P =.047) and absence of neurofibromatosis type 1 (P =.035). In the multivariate analysis of the 74 patients that remained on study after the first cycle of chemotherapy, factors associated with the risk of disease progression were age younger than 1 year at diagnosis (P =.0053) and no objective response to chemotherapy (P =.0029). Three-year PFS was 44% in infants < or = 1 year versus 66% in children older than 1 year. Three-year PFS was 53% in the absence of an objective response to chemotherapy versus 68% after a PR or CR. CONCLUSION: A significant proportion of children with OPT can avoid radiotherapy after prolonged chemotherapy. Deferring irradiation with chemotherapy protocols did not compromise overall survival of the entire population or visual function. |
| | |
Authors:
|
Véronique Laithier; Jacques Grill; Marie-Cécile Le Deley; Marie-Madeleine Ruchoux; Dominique Couanet; François Doz; Fabienne Pichon; Hervé Rubie; Didier Frappaz; Jean-Paul Vannier; Annie Babin-Boilletot; Eric Sariban; Pascal Chastagner; Michel Zerah; Marie-Anne Raquin; Olivier Hartmann; Chantal Kalifa; |
Related Documents
:
|
18827494 - Gender differences in treatment outcomes among patients with non-small cell lung cancer... 3531424 - Carboplatin (nsc-241-240): an active platinum analog for the treatment of squamous-cell... 11268454 - Paclitaxel and carboplatin for recurrent salivary gland malignancies. 12801044 - Mitomycin c, carboplatin and protracted venous infusion 5-fluorouracil in advanced oeso... 22115124 - Treatment of colorectal liver metastases. 17409894 - Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Volume: 21 ISSN: 0732-183X ISO Abbreviation: J. Clin. Oncol. Publication Date: 2003 Dec |
Date Detail:
|
Created Date: 2003-12-15 Completed Date: 2004-02-13 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8309333 Medline TA: J Clin Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 4572-8 Citation Subset: IM |
Affiliation:
|
Department of Pediatric and Adolescent Medicine, Insitut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Factors Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Chi-Square Distribution Child Child, Preschool Combined Modality Therapy Disease-Free Survival Factor Analysis, Statistical Female France Humans Infant Infant, Newborn Male Optic Nerve Neoplasms / drug therapy* Prospective Studies Survival Analysis |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional con...
Next Document: Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the N...